UBS Group
BIB icon

UBS Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

UBS Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82 Hold
1
– – ﹤0.01% 10145
2025
Q4 		$80 Hold
1
– – ﹤0.01% 10217
2025
Q3 		$60 Sell
1
-123
-99% -$6.62K ﹤0.01% 9995
2025
Q2 		$5.68K Buy
124
+123
+12,300% +$5.42K ﹤0.01% 9148
2025
Q1 		$48 Sell
1
-587
-100% -$31.5K ﹤0.01% 10016
2024
Q4 		$29.8K Buy
+588
New +$34.8K ﹤0.01% 7610
2024
Q3 		– Sell
-248
Closed -$14.7K – 9507
2024
Q2 		$14.7K Buy
248
+10
+4% +$553 ﹤0.01% 7499
2024
Q1 		$13.7K Buy
+238
New +$13.8K ﹤0.01% 7090
2023
Q4 		– Sell
-849
Closed -$40.7K – 9317
2023
Q3 		$40.7K Sell
849
-1,641
-66% -$84.3K ﹤0.01% 6430
2023
Q2 		$130K Buy
2,490
+524
+27% +$28.9K ﹤0.01% 5812
2023
Q1 		$107K Buy
1,966
+1,035
+111% +$58.4K ﹤0.01% 5871
2022
Q4 		$53.7K Sell
931
-220
-19% -$12.4K ﹤0.01% 6707
2022
Q3 		$55K Buy
1,151
+784
+214% +$41.8K ﹤0.01% 6253
2022
Q2 		$18K Sell
367
-1,667
-82% -$84.8K ﹤0.01% 6991
2022
Q1 		$126K Buy
2,034
+1,528
+302% +$93.8K ﹤0.01% 5719
2021
Q4 		$41K Buy
+506
New +$43.4K ﹤0.01% 7088
2021
Q3 		– Sell
-1,159
Closed -$114K – 9534
2021
Q2 		$114K Buy
1,159
+659
+132% +$57.5K ﹤0.01% 5776
2021
Q1 		$42K Buy
500
+87
+21% +$8.21K ﹤0.01% 6718
2020
Q4 		$36K Sell
413
-10,985
-96% -$850K ﹤0.01% 6472
2020
Q3 		$797K Buy
+11,398
New +$809K ﹤0.01% 3806
2020
Q2 		– Sell
-696
Closed -$32K – 7940
2020
Q1 		$32K Buy
696
+80
+13% +$4.46K ﹤0.01% 6161
2019
Q4 		$38K Sell
616
-987
-62% -$52.7K ﹤0.01% 6511
2019
Q3 		$68K Sell
1,603
-381
-19% -$18.1K ﹤0.01% 6001
2019
Q2 		$103K Buy
+1,984
New +$98.7K ﹤0.01% 5357
2019
Q1 		– Sell
-642
Closed -$27K – 7730
2018
Q4 		$27K Buy
+642
New +$33.5K ﹤0.01% 6556
2018
Q3 		– Sell
-1,444
Closed -$83K – 7972
2018
Q2 		$83K Sell
1,444
-237
-14% -$12.9K ﹤0.01% 5582
2018
Q1 		$93K Buy
1,681
+124
+8% +$7.43K ﹤0.01% 5264
2017
Q4 		$87K Buy
+1,557
New +$87.8K ﹤0.01% 5459
2017
Q2 		– Sell
-121
Closed -$6K – 7668
2017
Q1 		$6K Buy
+121
New +$5.63K ﹤0.01% 6883
2016
Q3 		– Sell
-1,991
Closed -$77K – 7672
2016
Q2 		$77K Sell
1,991
-1,364
-41% -$58.8K ﹤0.01% 5207
2016
Q1 		$137K Buy
3,355
+537
+19% +$23.7K ﹤0.01% 4750
2015
Q4 		$201K Buy
2,818
+1,966
+231% +$131K ﹤0.01% 4664
2015
Q3 		$50K Buy
+852
New +$72.6K ﹤0.01% 5828
2015
Q2 		– Sell
-3,716
Closed -$294K – 8487
2015
Q1 		$294K Buy
3,716
+542
+17% +$40.2K ﹤0.01% 4571
2014
Q4 		$199K Buy
+3,174
New +$186K ﹤0.01% 5050

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group's BIB Position: Q1 2026 in Review

UBS Group held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q1 2026 at 1 share worth $82. The position accounts for ﹤0.01% of the portfolio, ranked #10145.

UBS Group first reported a position in BIB in Q4 2014 and has held it in 35 quarters since. The position peaked at $797K in Q3 2020. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • UBS Group held 1 share of ProShares Ultra NASDAQ Biotechnology worth $82 as of Q1 2026.
  • UBS Group left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10145 holding.
  • UBS Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and has held it in 35 quarters since.
  • UBS Group's ProShares Ultra NASDAQ Biotechnology position peaked at $797K in Q3 2020.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.